NZ787393A - New methylquinazolinone derivatives - Google Patents
New methylquinazolinone derivativesInfo
- Publication number
- NZ787393A NZ787393A NZ787393A NZ78739320A NZ787393A NZ 787393 A NZ787393 A NZ 787393A NZ 787393 A NZ787393 A NZ 787393A NZ 78739320 A NZ78739320 A NZ 78739320A NZ 787393 A NZ787393 A NZ 787393A
- Authority
- NZ
- New Zealand
- Prior art keywords
- methylquinazolinone
- derivatives
- new
- compound
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Combines (AREA)
- Harvester Elements (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19214941 | 2019-12-10 | ||
| PCT/EP2020/084976 WO2021116055A1 (en) | 2019-12-10 | 2020-12-08 | New methylquinazolinone derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ787393A true NZ787393A (en) | 2025-07-25 |
Family
ID=68848113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ787393A NZ787393A (en) | 2019-12-10 | 2020-12-08 | New methylquinazolinone derivatives |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US12116349B2 (enExample) |
| EP (2) | EP4483882A3 (enExample) |
| JP (2) | JP7108146B2 (enExample) |
| KR (1) | KR102836833B1 (enExample) |
| CN (2) | CN114787156B (enExample) |
| AR (1) | AR122351A1 (enExample) |
| AU (1) | AU2020403443B2 (enExample) |
| CA (1) | CA3162883A1 (enExample) |
| CL (1) | CL2022001529A1 (enExample) |
| CO (1) | CO2022008968A2 (enExample) |
| CR (1) | CR20220251A (enExample) |
| DK (1) | DK4073065T3 (enExample) |
| ES (1) | ES3023264T3 (enExample) |
| FI (1) | FI4073065T3 (enExample) |
| HR (1) | HRP20250418T1 (enExample) |
| HU (1) | HUE071148T2 (enExample) |
| IL (2) | IL292161B2 (enExample) |
| LT (1) | LT4073065T (enExample) |
| MA (1) | MA58087B1 (enExample) |
| MX (1) | MX2022006783A (enExample) |
| NZ (1) | NZ787393A (enExample) |
| PE (1) | PE20221778A1 (enExample) |
| PH (1) | PH12022551119A1 (enExample) |
| PL (1) | PL4073065T3 (enExample) |
| PT (1) | PT4073065T (enExample) |
| RS (1) | RS66721B1 (enExample) |
| SI (1) | SI4073065T1 (enExample) |
| TW (1) | TWI877268B (enExample) |
| UA (1) | UA128299C2 (enExample) |
| WO (1) | WO2021116055A1 (enExample) |
| ZA (2) | ZA202204675B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102836833B1 (ko) * | 2019-12-10 | 2025-07-22 | 에프. 호프만-라 로슈 아게 | 신규 메틸퀴나졸리논 유도체 |
| KR20220112777A (ko) * | 2019-12-10 | 2022-08-11 | 에프. 호프만-라 로슈 아게 | 패러독스 파괴제로서의 새로운 braf 억제제 |
| CN116096710B (zh) | 2020-06-09 | 2025-07-25 | 阿雷生物药品公司 | 用于治疗braf相关疾病和障碍的4-氧代-3,4-二氢喹唑啉酮化合物 |
| EP4351583A4 (en) | 2021-06-08 | 2025-06-04 | C4 Therapeutics, Inc. | THERAPEUTICS TO DEGRADE MUTANT BRAF |
| TW202313046A (zh) * | 2021-06-09 | 2023-04-01 | 瑞士商赫孚孟拉羅股份公司 | 用於癌症治療之組合療法 |
| AU2022289684A1 (en) * | 2021-06-09 | 2023-10-05 | F. Hoffmann-La Roche Ag | Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer |
| CA3222612A1 (en) * | 2021-06-09 | 2022-12-15 | F. Hoffmann-La Roche Ag | New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide |
| JPWO2023008462A1 (enExample) | 2021-07-27 | 2023-02-02 | ||
| AU2022383040A1 (en) | 2021-11-04 | 2024-03-07 | F. Hoffmann-La Roche Ag | Novel use of quinazolinone compound for the treatment of cancer |
| TW202409040A (zh) | 2022-07-19 | 2024-03-01 | 大陸商西藏海思科製藥有限公司 | 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途 |
| WO2024105144A1 (en) | 2022-11-18 | 2024-05-23 | F. Hoffmann-La Roche Ag | Quinazolinone compound as braf inhibitor for the treatment of advanced solid cancer or metastases |
| EP4634172A1 (en) * | 2022-12-15 | 2025-10-22 | F. Hoffmann-La Roche AG | Combination therapy for cancer treatment |
| EP4634171A1 (en) * | 2022-12-15 | 2025-10-22 | F. Hoffmann-La Roche AG | Process for the preparation of a quinazolinone derivative |
| AU2024289011A1 (en) | 2023-07-04 | 2025-12-18 | F. Hoffmann-La Roche Ag | New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]- 3-fluoro-pyrrolidine-1-sulfonamide |
| WO2025108405A1 (zh) * | 2023-11-22 | 2025-05-30 | 西藏海思科制药有限公司 | 作为激酶抑制剂的喹唑啉酮衍生物的制备及其用途 |
| WO2025153057A1 (zh) * | 2024-01-17 | 2025-07-24 | 海思科医药集团股份有限公司 | 一种含braf抑制剂的药物组合物及其在医药上的应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4429085B2 (ja) | 2004-06-08 | 2010-03-10 | 有限会社コンペックス | 茸栽培用殺菌菌床組成物の製造法及び茸栽培法 |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| GB0525069D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| SG183036A1 (en) | 2007-07-17 | 2012-08-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| PT2947072T (pt) | 2008-03-17 | 2016-12-06 | Ambit Biosciences Corp | 1-(3-(6,7-dimetoxiquinazolin-4-iloxi)fenil)-3-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il)ureia como modulador da cinase raf no tratamento de doenças oncológicas |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| TW201041888A (en) | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| WO2012118492A1 (en) * | 2011-03-01 | 2012-09-07 | Array Biopharma Inc. | Heterocyclic sulfonamides as raf inhibitors |
| AR091876A1 (es) | 2012-07-26 | 2015-03-04 | Novartis Ag | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas |
| JP6186440B2 (ja) | 2012-09-19 | 2017-08-23 | ノバルティス アーゲー | キナーゼ阻害剤としてのジヒドロピロリジノピリミジン |
| BR112015028845A2 (pt) | 2013-05-30 | 2017-07-25 | Plexxikon Inc | compostos para a modulação da quinase e indicações da mesma |
| WO2016191296A1 (en) * | 2015-05-22 | 2016-12-01 | Plexxikon Inc. | Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases |
| SI3359541T1 (sl) | 2015-10-09 | 2021-01-29 | Abbvie Overseas S.A R.L. | N-sulfonirani pirazolo(3,4 b)piridin-6-karboksamidi in postopki uporabe |
| RU2687107C1 (ru) | 2018-06-18 | 2019-05-07 | федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" | Ингибитор braf киназы n-(3-(5-(4-хлорофенил)-1h-пиразоло[3,4-b]пиридин-3-карбонил)-2,4-дифторофенил) пропан-1-сульфонамид |
| TWI748317B (zh) | 2019-01-03 | 2021-12-01 | 美商建南德克公司 | 吡啶并－嘧啶酮與喋啶酮化合物及使用方法 |
| TWI817018B (zh) * | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | 用於治療ｂｒａｆ相關的疾病和失調症之化合物 |
| KR102836833B1 (ko) | 2019-12-10 | 2025-07-22 | 에프. 호프만-라 로슈 아게 | 신규 메틸퀴나졸리논 유도체 |
| KR20220112777A (ko) | 2019-12-10 | 2022-08-11 | 에프. 호프만-라 로슈 아게 | 패러독스 파괴제로서의 새로운 braf 억제제 |
| CN116096710B (zh) | 2020-06-09 | 2025-07-25 | 阿雷生物药品公司 | 用于治疗braf相关疾病和障碍的4-氧代-3,4-二氢喹唑啉酮化合物 |
| JP2023554062A (ja) | 2020-12-18 | 2023-12-26 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 新規アリール－ピリド－ピリミジン－オン誘導体 |
| EP4263518A1 (en) | 2020-12-18 | 2023-10-25 | F. Hoffmann-La Roche AG | New quinazolinone derivatives |
| EP4351583A4 (en) | 2021-06-08 | 2025-06-04 | C4 Therapeutics, Inc. | THERAPEUTICS TO DEGRADE MUTANT BRAF |
| JP2024545073A (ja) | 2021-12-08 | 2024-12-05 | アレイ バイオファーマ インコーポレイテッド | Ｎ－（２－クロロ－３－（（５－クロロ－３－メチル－４－オキソ－３，４－ジヒドロキナゾリン－６－イル）アミノ）－４－フルオロフェニル）－３－フルオロアゼチジン－１－スルホンアミドの結晶形態 |
-
2020
- 2020-12-08 KR KR1020227023074A patent/KR102836833B1/ko active Active
- 2020-12-08 PE PE2022000853A patent/PE20221778A1/es unknown
- 2020-12-08 IL IL292161A patent/IL292161B2/en unknown
- 2020-12-08 HR HRP20250418TT patent/HRP20250418T1/hr unknown
- 2020-12-08 HU HUE20817377A patent/HUE071148T2/hu unknown
- 2020-12-08 CR CR20220251A patent/CR20220251A/es unknown
- 2020-12-08 AU AU2020403443A patent/AU2020403443B2/en active Active
- 2020-12-08 LT LTEPPCT/EP2020/084976T patent/LT4073065T/lt unknown
- 2020-12-08 RS RS20250354A patent/RS66721B1/sr unknown
- 2020-12-08 PL PL20817377.3T patent/PL4073065T3/pl unknown
- 2020-12-08 MA MA58087A patent/MA58087B1/fr unknown
- 2020-12-08 WO PCT/EP2020/084976 patent/WO2021116055A1/en not_active Ceased
- 2020-12-08 PT PT208173773T patent/PT4073065T/pt unknown
- 2020-12-08 CA CA3162883A patent/CA3162883A1/en active Pending
- 2020-12-08 DK DK20817377.3T patent/DK4073065T3/da active
- 2020-12-08 EP EP24205932.7A patent/EP4483882A3/en active Pending
- 2020-12-08 CN CN202080084994.3A patent/CN114787156B/zh active Active
- 2020-12-08 EP EP20817377.3A patent/EP4073065B1/en active Active
- 2020-12-08 FI FIEP20817377.3T patent/FI4073065T3/fi active
- 2020-12-08 MX MX2022006783A patent/MX2022006783A/es unknown
- 2020-12-08 CN CN202410878222.7A patent/CN118791472A/zh active Pending
- 2020-12-08 SI SI202030605T patent/SI4073065T1/sl unknown
- 2020-12-08 ES ES20817377T patent/ES3023264T3/es active Active
- 2020-12-08 UA UAA202202163A patent/UA128299C2/uk unknown
- 2020-12-08 IL IL316473A patent/IL316473A/en unknown
- 2020-12-08 JP JP2021566023A patent/JP7108146B2/ja active Active
- 2020-12-08 PH PH1/2022/551119A patent/PH12022551119A1/en unknown
- 2020-12-08 NZ NZ787393A patent/NZ787393A/en unknown
- 2020-12-09 AR ARP200103417A patent/AR122351A1/es unknown
- 2020-12-09 TW TW109143500A patent/TWI877268B/zh active
-
2021
- 2021-12-14 JP JP2021202780A patent/JP2022124458A/ja active Pending
-
2022
- 2022-04-26 ZA ZA2022/04675A patent/ZA202204675B/en unknown
- 2022-06-08 US US17/835,245 patent/US12116349B2/en active Active
- 2022-06-09 CL CL2022001529A patent/CL2022001529A1/es unknown
- 2022-06-22 ZA ZA2022/06923A patent/ZA202206923B/en unknown
- 2022-06-28 CO CONC2022/0008968A patent/CO2022008968A2/es unknown
-
2023
- 2023-11-30 US US18/525,536 patent/US20240174621A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ787393A (en) | New methylquinazolinone derivatives | |
| MY208549A (en) | Parp1 inhibitors | |
| SA522432955B1 (ar) | Kras g12c مثبطات | |
| PH12020551464A1 (en) | Cd73 inhibitors | |
| MX371167B (es) | Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta). | |
| MX2021008342A (es) | Derivados de pirazol como inhibidores de calicreina plasmatica. | |
| ZA202201364B (en) | Deuterated compounds for use in the treatment of cancer | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| SA519410865B1 (ar) | مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه | |
| MX2018011100A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas. | |
| ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| MX382162B (es) | Combinaciones farmacéuticas de un inhibidor de enzima hdac con un inhibidor de proteasoma, y su uso en el tratamiento de cáncer. | |
| PH12022550130A1 (en) | Enzyme inhibitors | |
| MX2023014492A (es) | Compuestos utiles en la terapia para el vih. | |
| MX2024005107A (es) | Nuevo uso de compuesto de quinazolinona para el tratamiento de cancer. | |
| PH12022551241A1 (en) | Egfr inhibitors | |
| MX2024008115A (es) | Tratamiento conjunto para tratamiento contra el cancer. | |
| MX389786B (es) | Derivados de 4-metil 7-{[5-heterociclilpirazina-2-il]amino}1,2- dihidro-1,6-naftiridina-5-ona como compuestos inhibidores de cdk4/6 y el uso de los mismos para el tratamiento de cáncer. | |
| PH12022550118A1 (en) | Enzyme inhibitors | |
| ZA202212095B (en) | Il4i1 inhibitors and methods of use | |
| MX2025001982A (es) | Inhibidores de kif18a y usos de estos | |
| MX2022000390A (es) | Derivados macrociclicos espirociclicos como inhibidores de mcl-1. | |
| AU2016363719A8 (en) | 1,3,4-thiadiazole compounds and their use in treating cancer | |
| PH12021551590A1 (en) | Quinoline compounds as inhibitors of tam and met kinases | |
| MX2020008273A (es) | Inhibidores de la cinasa del complejo de activacion transcripcional notch ("nack") y metodos para el uso de los mismos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 DEC 2026 BY ANAQUA SERVICES Effective date: 20251120 |